Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Plos One
|
May 19, 2012
Induction of cellular senescence by doxorubicin is associated with upregulated miR-375 and induction of autophagy in K562 cells
Ming-Yu Yang, Pai-Mei Lin, Yi-Chang Liu, et al.
Annals of Hematology
|
October 31, 2013
Breakthrough Fusarium solani infection in a patient with acute myeloid leukemia receiving posaconazole prophylaxis
Cheng-Han Wu, Po-Liang Lu, Hui-Hua Hsiao, et al.
International Journal of Medical Sciences
|
November 9, 2020
Pin1 coordinates HDAC6 upregulation with cell migration in lung cancer cells
Hsiang-Hao Chuang, Jui-Feng Hsu, Hsu-Liang Chang, et al.
World Journal of Surgical Oncology
|
October 1, 2015
Port type is a possible risk factor for implantable venous access port-related bloodstream infections and no sign of local infection predicts the growth of gram-negative bacilli
Jui-Feng Hsu, Hsu-Liang Chang, Ming-Ju Tsai, et al.
Journal of Biological Rhythms
|
April 2, 2011
Altered expression of circadian clock genes in human chronic myeloid leukemia
Ming-Yu Yang, Wen-Chi Yang, Pai-Mei Lin, et al.
Asia-Pacific Journal of Clinical Oncology
|
January 30, 2019
Clinical efficacy of concurrent bevacizumab for malignant ascites in nonsquamous cell carcinoma of the lung
Jui-Feng Hsu, Yen-Lung Lee, Hsu-Liang Chang, et al.
BMC Pharmacology & Toxicology
|
December 15, 2017
The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
Chih-Jen Yang, Ming-Ju Tsai, Jen-Yu Hung, et al.
Molecular Carcinogenesis
|
July 3, 2013
MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib
Yi-Chang Liu, Hui-Hua Hsiao, Wen-Chi Yang, et al.
Anticancer Research
|
December 6, 2015
Up-regulation of PER3 Expression Is Correlated with Better Clinical Outcome in Acute Leukemia
Ming-Yu Yang, Pai-Mei Lin, Hui-Hua Hsiao, et al.
Anticancer Research
|
October 15, 2013
Outcome of allotransplants in patients with chronic-phase chronic myeloid leukemia following imatinib failure: prognosis revisited
Yi-Chang Liu, Hui-Hua Hsiao, Chao-Sung Chang, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Plos One
|
May 19, 2012
Induction of cellular senescence by doxorubicin is associated with upregulated miR-375 and induction of autophagy in K562 cells
Ming-Yu Yang, Pai-Mei Lin, Yi-Chang Liu, et al.
Annals of Hematology
|
October 31, 2013
Breakthrough Fusarium solani infection in a patient with acute myeloid leukemia receiving posaconazole prophylaxis
Cheng-Han Wu, Po-Liang Lu, Hui-Hua Hsiao, et al.
International Journal of Medical Sciences
|
November 9, 2020
Pin1 coordinates HDAC6 upregulation with cell migration in lung cancer cells
Hsiang-Hao Chuang, Jui-Feng Hsu, Hsu-Liang Chang, et al.
World Journal of Surgical Oncology
|
October 1, 2015
Port type is a possible risk factor for implantable venous access port-related bloodstream infections and no sign of local infection predicts the growth of gram-negative bacilli
Jui-Feng Hsu, Hsu-Liang Chang, Ming-Ju Tsai, et al.
Journal of Biological Rhythms
|
April 2, 2011
Altered expression of circadian clock genes in human chronic myeloid leukemia
Ming-Yu Yang, Wen-Chi Yang, Pai-Mei Lin, et al.
Asia-Pacific Journal of Clinical Oncology
|
January 30, 2019
Clinical efficacy of concurrent bevacizumab for malignant ascites in nonsquamous cell carcinoma of the lung
Jui-Feng Hsu, Yen-Lung Lee, Hsu-Liang Chang, et al.
BMC Pharmacology & Toxicology
|
December 15, 2017
The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
Chih-Jen Yang, Ming-Ju Tsai, Jen-Yu Hung, et al.
Molecular Carcinogenesis
|
July 3, 2013
MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib
Yi-Chang Liu, Hui-Hua Hsiao, Wen-Chi Yang, et al.
Anticancer Research
|
December 6, 2015
Up-regulation of PER3 Expression Is Correlated with Better Clinical Outcome in Acute Leukemia
Ming-Yu Yang, Pai-Mei Lin, Hui-Hua Hsiao, et al.
Anticancer Research
|
October 15, 2013
Outcome of allotransplants in patients with chronic-phase chronic myeloid leukemia following imatinib failure: prognosis revisited
Yi-Chang Liu, Hui-Hua Hsiao, Chao-Sung Chang, et al.
Page
of 3